Floatz logo

PEGFILGRASTIM

Peritoneal Cavity Cancer

TORL Biotherapeutics, LLCprotein_peptidePhase 2/3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

153 Active assets in the Peritoneal Cavity Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Inno-206
Case Comprehensive Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →